A committee of American experts ruled on Tuesday in favor of a vaccine recall specifically targeting the Omicron variant of SARS-CoV-2. This decision suggests a need for annual injections once morest Covid-19, like the flu.
The scientists, invited by the American drug agency, the FDA, approved the measure by 19 votes to 2 following a day spent reviewing the available data, including projections for future waves and preliminary results provided by vaccine manufacturers.
An FDA scientist summed up the complexity of the situation: anticipating the evolution of a virus that has often defied predictions and mutated even faster than the flu. “We are working in a very complicated area today, because none of us have a crystal ball,” he said.
Broad targeted protection
A member of the committee, Professor of Medicine Michael Nelson of the University of Virginia said he voted in favor of the measure, because he feared that the declining effectiveness of vaccines might translate into serious cases for those at risk. ‘We must take action without delay.’
Pfizer and Moderna, which recently announced that their vaccines developed specifically once morest the Omicron variant showed promising results, addressed the expert committee on Tuesday, as did Novavax.
Most scientists seemed to favor a vaccine that would target both the first strain of the virus, to achieve broad protection, and the latest Omicron BA.4 and BA.5 subvariants. Pfizer and Moderna said they would be able to move into production of such vaccines within three months.
Unlike the Alpha and Delta variants, which eventually declined, Omicron and its subvariants dominated infections in the year 2022, so much so that they now account for the vast majority of infections worldwide, said to the Jerry Weir committee of the FDA.
/ATS
